Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma ...

In 1962, a pediatric neurology resident at Columbia's Neurological Institute and his colleagues in the College of Physicians ...

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.

FDA moves to speed biosimilar approvals by eliminating comparative studies, aiming to lower drug costs and increase ...

The Boston biotech founded by Harvard professor David Sinclair is testing whether cellular reprogramming can turn back the ...

Shortly after taking reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling ...

The latest in a trend of companies stepping back from cell and gene therapies amid regulatory uncertainty and manufacturing ...

Intellia Therapeutics has temporarily stopped dosing and patient screening in two late-stage studies of its gene therapy after a participant developed serious liver injury, the company said on Monday, ...

Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...